GeneDx Faces Class Action Lawsuit, Shares Plunge 50%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: Globenewswire
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against GeneDx, alleging that the company made false statements between April 16, 2025, and May 4, 2026, misleading investors about its financial health and impacting shareholder rights.
- Financial Losses: GeneDx reported a Q1 2026 loss of -$0.28 per share and an operational loss of $57.5 million, while also lowering its 2026 revenue guidance by approximately $65 million, indicating a severe decline in profitability.
- Stock Price Plunge: Following the release of disappointing financial results, GeneDx's stock price fell from $67.93 on May 4, 2026, to $34.51, a drop of about 50%, reflecting market pessimism regarding the company's future prospects.
- Strategic Adjustments: The company recorded a $31.3 million write-down related to goodwill due to downward revisions in cash flow forecasts for its Fabric Genomics unit, highlighting significant challenges in its business strategy and market execution that could affect future competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 69.120
Low
155.00
Averages
171.43
High
200.00
Current: 69.120
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must seek lead plaintiff status by August 3, 2026, highlighting investor concerns over potential legal risks associated with the company.
- Acquisition Impact: GeneDx announced the acquisition of Fabric Genomics in April 2025, but the lawsuit alleges that the company failed to disclose significant issues with Fabric Genomics that could negatively affect GeneDx's overall business, indicating potential risks in acquisition decisions.
- Declining Financial Performance: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69% and a reduction in projected earnings from $540-$555 million to $475-$490 million, leading to a stock price drop of over 49% following the announcement, reflecting market concerns about the company's financial health.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength and influence in securities fraud cases, which may significantly impact the outcome of the GeneDx lawsuit.
See More
GeneDx Faces Class Action Lawsuit, Shares Plunge 50%
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against GeneDx, alleging that the company made false statements between April 16, 2025, and May 4, 2026, misleading investors about its financial health and impacting shareholder rights.
- Financial Losses: GeneDx reported a Q1 2026 loss of -$0.28 per share and an operational loss of $57.5 million, while also lowering its 2026 revenue guidance by approximately $65 million, indicating a severe decline in profitability.
- Stock Price Plunge: Following the release of disappointing financial results, GeneDx's stock price fell from $67.93 on May 4, 2026, to $34.51, a drop of about 50%, reflecting market pessimism regarding the company's future prospects.
- Strategic Adjustments: The company recorded a $31.3 million write-down related to goodwill due to downward revisions in cash flow forecasts for its Fabric Genomics unit, highlighting significant challenges in its business strategy and market execution that could affect future competitiveness.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit filed by investors who allege that the company made significant misstatements regarding its acquisition of Fabric Genomics between April 16, 2025, and May 4, 2026, impacting investor decisions.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market and revenue streams through Fabric's software platform; however, the lawsuit claims that GeneDx failed to disclose critical viability issues with Fabric.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, revealing a $31.3 million impairment loss related to Fabric, which caused its stock price to plummet by over 49% following the announcement.
- Investor Action: Investors are encouraged to file for lead plaintiff status by August 3, 2026, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and operating on a contingency fee basis, urging investors to take action to protect their rights.
See More
GeneDx Faces Class Action Over Fabric Genomics Acquisition Misrepresentation
- Stock Price Collapse: GeneDx's stock plummeted 49% on May 5, 2026, following a disastrous Q1 earnings report that included a $31.2 million impairment charge, indicating a strategic failure in the Fabric Genomics acquisition that severely undermined investor confidence.
- Financial Performance Decline: The company reported a significant tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing revenue targets by $2.5 million, reflecting a lack of expected synergies and impacting future profitability.
- Leadership Changes: Following the stock crash, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to prior failures, which could affect corporate governance and strategic direction moving forward.
- Investor Lawsuit: Hagens Berman is initiating a securities class action against GeneDx, alleging misleading statements to investors, urging affected investors to contact the firm by August 3, highlighting the potential for increased legal risks that may further strain the company's financial situation.
See More
Notice of Class Action Lawsuit for GeneDx Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability negatively impacted GeneDx's overall operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
- Investor Advisory: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in securities class actions to ensure optimal representation and support during litigation.
See More
GeneDx's Fabric Genomics Acquisition Leads to Stock Plunge
- Severe Acquisition Consequences: Following the acquisition of Fabric Genomics, GeneDx Holdings Corp. experienced a 49.20% stock plunge on May 4, 2026, resulting in a $31.2 million impairment charge that severely undermined investor confidence.
- Significant Revenue Guidance Cut: The company slashed its full-year revenue guidance for 2026 by approximately $65 million to $490 million, indicating that integration progress fell short of expectations, which could lead to ongoing pressure on future cash flows and profitability.
- Market Reaction Intensifies: During the October 2025 earnings call, the company reported adjusted gross margins of 74%, but subsequent results revealed a decline to 69%, reflecting increasing market concerns about the company's financial health.
- Increased Legal Litigation Risks: With allegations of misleading statements during the acquisition process, investors face the risk of a class-action lawsuit, with a deadline of August 3, 2026, further exacerbating market uncertainty.
See More
GeneDx Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must seek lead plaintiff status by August 3, 2026, highlighting investor concerns over potential legal risks associated with the company.
- Acquisition Impact: GeneDx announced the acquisition of Fabric Genomics in April 2025, but the lawsuit alleges that the company failed to disclose significant issues with Fabric Genomics that could negatively affect GeneDx's overall business, indicating potential risks in acquisition decisions.
- Declining Financial Performance: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69% and a reduction in projected earnings from $540-$555 million to $475-$490 million, leading to a stock price drop of over 49% following the announcement, reflecting market concerns about the company's financial health.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength and influence in securities fraud cases, which may significantly impact the outcome of the GeneDx lawsuit.
See More
GeneDx Faces Class Action Lawsuit, Shares Plunge 50%
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against GeneDx, alleging that the company made false statements between April 16, 2025, and May 4, 2026, misleading investors about its financial health and impacting shareholder rights.
- Financial Losses: GeneDx reported a Q1 2026 loss of -$0.28 per share and an operational loss of $57.5 million, while also lowering its 2026 revenue guidance by approximately $65 million, indicating a severe decline in profitability.
- Stock Price Plunge: Following the release of disappointing financial results, GeneDx's stock price fell from $67.93 on May 4, 2026, to $34.51, a drop of about 50%, reflecting market pessimism regarding the company's future prospects.
- Strategic Adjustments: The company recorded a $31.3 million write-down related to goodwill due to downward revisions in cash flow forecasts for its Fabric Genomics unit, highlighting significant challenges in its business strategy and market execution that could affect future competitiveness.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit filed by investors who allege that the company made significant misstatements regarding its acquisition of Fabric Genomics between April 16, 2025, and May 4, 2026, impacting investor decisions.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market and revenue streams through Fabric's software platform; however, the lawsuit claims that GeneDx failed to disclose critical viability issues with Fabric.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, revealing a $31.3 million impairment loss related to Fabric, which caused its stock price to plummet by over 49% following the announcement.
- Investor Action: Investors are encouraged to file for lead plaintiff status by August 3, 2026, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and operating on a contingency fee basis, urging investors to take action to protect their rights.
See More
GeneDx Faces Class Action Over Fabric Genomics Acquisition Misrepresentation
- Stock Price Collapse: GeneDx's stock plummeted 49% on May 5, 2026, following a disastrous Q1 earnings report that included a $31.2 million impairment charge, indicating a strategic failure in the Fabric Genomics acquisition that severely undermined investor confidence.
- Financial Performance Decline: The company reported a significant tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing revenue targets by $2.5 million, reflecting a lack of expected synergies and impacting future profitability.
- Leadership Changes: Following the stock crash, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to prior failures, which could affect corporate governance and strategic direction moving forward.
- Investor Lawsuit: Hagens Berman is initiating a securities class action against GeneDx, alleging misleading statements to investors, urging affected investors to contact the firm by August 3, highlighting the potential for increased legal risks that may further strain the company's financial situation.
See More
Notice of Class Action Lawsuit for GeneDx Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, to apply as lead plaintiffs by August 3, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that GeneDx made false statements regarding the acquisition of Fabric, misleading investors into believing it would enhance financial performance, while significant issues with Fabric's viability negatively impacted GeneDx's overall operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
- Investor Advisory: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in securities class actions to ensure optimal representation and support during litigation.
See More
GeneDx's Fabric Genomics Acquisition Leads to Stock Plunge
- Severe Acquisition Consequences: Following the acquisition of Fabric Genomics, GeneDx Holdings Corp. experienced a 49.20% stock plunge on May 4, 2026, resulting in a $31.2 million impairment charge that severely undermined investor confidence.
- Significant Revenue Guidance Cut: The company slashed its full-year revenue guidance for 2026 by approximately $65 million to $490 million, indicating that integration progress fell short of expectations, which could lead to ongoing pressure on future cash flows and profitability.
- Market Reaction Intensifies: During the October 2025 earnings call, the company reported adjusted gross margins of 74%, but subsequent results revealed a decline to 69%, reflecting increasing market concerns about the company's financial health.
- Increased Legal Litigation Risks: With allegations of misleading statements during the acquisition process, investors face the risk of a class-action lawsuit, with a deadline of August 3, 2026, further exacerbating market uncertainty.
See More
